Lian J, Guoping C, Shapiro S S, Tran L P, Beacham D A
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Exp Cell Res. 1999 Oct 10;252(1):114-22. doi: 10.1006/excr.1999.4612.
We have previously shown that, in addition to the vitronectin receptor (VNR, alpha(v)beta(3)), the GP Ib complex can participate in endothelial cell (EC) attachment to von Willebrand Factor (vWF) (D. A. Beacham, M. S. Cruz, and R. I. Handin, 1995, Thromb. Haemostas. 73, 309-317; D. A. Beacham, L.-P. Tran, and S. S. Shapiro, 1997, Blood 89, 4071-4077). In this study we have investigated the functional roles of these vWF receptors in the migration of untreated and TNFalpha-treated EC on vWF, a mixture of vWF and type I collagen, and on vitronectin (VN). In agreement with previous studies (D. I. Leavesley, M. A. Schwartz, M. Rosenfeld, and D. A. Cheresh, 1993, J. Cell Biol. 121, 163-170), the migration of untreated and TNFalpha-treated EC on VN was dependent entirely on the VNR. Migration of untreated EC on vWF was inhibited 10-15% by recombinant vWF-A1, the GP Ibalpha-binding domain on vWF which abrogates the platelet GP Ibalpha-vWF interaction. In contrast, migration of TNFalpha-treated EC on vWF was inhibited 50-60% by vWF-A1 or the anti-GP Ibalpha mAb AS-7 but only 20% by the anti-VNR mAb LM609. On a mixed vWF-collagen substratum, vWF-A1 inhibited untreated EC migration by 45%, and TNFalpha-treated EC migration by 75%. The possible role of EC proliferation was eliminated, since hydroxyurea completely inhibited EC proliferation without reducing migration significantly. The anti-GP Ibalpha mAb Ib1 inhibited EC migration by 50%, but reduced proliferation by only 15%. Taken together, our data demonstrate that EC migration on vWF-containing substrata involves the GP Ib complex as well as the VNR and raises the possibility that the VNR and GP Ib act cooperatively in supporting EC migration.
我们先前已经表明,除了玻连蛋白受体(VNR,α(v)β(3))之外,糖蛋白Ib复合物(GP Ib complex)也能够参与内皮细胞(EC)与血管性血友病因子(vWF)的黏附(D. A. 比彻姆、M. S. 克鲁兹和R. I. 汉丁,1995年,《血栓与止血学》73卷,309 - 317页;D. A. 比彻姆、L.-P. 陈和S. S. 夏皮罗,1997年,《血液》89卷,4071 - 4077页)。在本研究中,我们研究了这些vWF受体在未处理的和经肿瘤坏死因子α(TNFα)处理的EC在vWF、vWF与I型胶原的混合物以及玻连蛋白(VN)上迁移过程中的功能作用。与先前的研究一致(D. I. 利夫斯利、M. A. 施瓦茨、M. 罗森菲尔德和D. A. 切雷什,1993年,《细胞生物学杂志》121卷,163 - 170页),未处理的和经TNFα处理的EC在VN上的迁移完全依赖于VNR。重组vWF - A1可抑制未处理的EC在vWF上10% - 15%的迁移,vWF - A1是vWF上与糖蛋白Ibalpha结合的结构域,它可消除血小板糖蛋白Ibalpha与vWF的相互作用。相比之下,vWF - A1或抗糖蛋白Ibalpha单克隆抗体AS - 7可抑制经TNFα处理的EC在vWF上50% - 60%的迁移,但抗VNR单克隆抗体LM609只能抑制20%。在vWF - 胶原混合基质上,vWF - A1可抑制未处理的EC迁移45%,抑制经TNFα处理的EC迁移75%。由于羟基脲完全抑制EC增殖但未显著降低迁移,所以排除了EC增殖的可能作用。抗糖蛋白Ibalpha单克隆抗体Ib1可抑制EC迁移50%,但仅使增殖降低15%。综上所述,我们的数据表明,EC在含vWF的基质上的迁移涉及GP Ib复合物以及VNR,并增加了VNR和GP Ib在支持EC迁移中协同作用的可能性。